长风药业(02652)自主研发的吸入粉雾剂候选药物ICF001的IND申请获NMPA受理

智通财经03-13

智通财经APP讯，长风药业(02652)公布，公司自主研发的吸入粉雾剂候选药物ICF001的新药临床试验(IND)申请已获中华人民共和国国家药品监督管理局(NMPA)受理。据悉，ICF001是一款基于前药技术平台自主研发的创新型长效吸入粉雾剂候选药物，专为治疗肺动脉高压及相关严重肺部疾病而设计。在分子设计与作用机制上，该产品透过特定化学修饰将活性分子转化为前药，使其在吸入沉积于肺部后，依赖肺组织...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2619882190?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-13 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619882190","market":"fut","top_or_hot":-1,"title":"长风药业(02652)自主研发的吸入粉雾剂候选药物ICF001的IND申请获NMPA受理","media":"智通财经","content":"<div>\n<p>智通财经APP讯，长风药业(02652)公布，公司自主研发的吸入粉雾剂候选药物ICF001的新药临床试验(IND)申请已获中华人民共和国国家药品监督管理局(NMPA)受理。据悉，ICF001是一款基于前药技术平台自主研发的创新型长效吸入粉雾剂候选药物，专为治疗肺动脉高压及相关严重肺部疾病而设计。在分子设计与作用机制上，该产品透过特定化学修饰将活性分子转化为前药，使其在吸入沉积于肺部后，依赖肺组织...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1413866.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>长风药业(02652)自主研发的吸入粉雾剂候选药物ICF001的IND申请获NMPA受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n长风药业(02652)自主研发的吸入粉雾剂候选药物ICF001的IND申请获NMPA受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-13 21:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1413866.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，长风药业(02652)公布，公司自主研发的吸入粉雾剂候选药物ICF001的新药临床试验(IND)申请已获中华人民共和国国家药品监督管理局(NMPA)受理。据悉，ICF001是一款基于前药技术平台自主研发的创新型长效吸入粉雾剂候选药物，专为治疗肺动脉高压及相关严重肺部疾病而设计。在分子设计与作用机制上，该产品透过特定化学修饰将活性分子转化为前药，使其在吸入沉积于肺部后，依赖肺组织...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1413866.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1413866.html","article_id":"2619882190","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619882190","pubTimestamp":1773406944,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，长风药业 公布，公司自主研发的吸入粉雾剂候选药物ICF001的新药临床试验申请已获中华人民共和国国家药品监督管理局受理。据悉，ICF001是一款基于前药技术平台自主研发的创新型长效吸入粉雾剂候选药物，专为治疗肺动脉高压及相关严重肺部疾病而设计。ICF001的首发适应症为动脉性肺动脉高压与间质性肺疾病相关肺动脉高压。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02652":"长风药业","IND":"Xtrackers Nifty 500 India ETF","BK1191":"制药"},"translate_title":"The IND application of ICF001, a drug candidate for inhalation powder spray independently developed by Changfeng Pharmaceutical (02652), was accepted by NMPA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IND":1.5,"02652":1.5},"content_text":"智通财经APP讯，长风药业(02652)公布，公司自主研发的吸入粉雾剂候选药物ICF001的新药临床试验(IND)申请已获中华人民共和国国家药品监督管理局(NMPA)受理。据悉，ICF001是一款基于前药技术平台自主研发的创新型长效吸入粉雾剂候选药物，专为治疗肺动脉高压及相关严重肺部疾病而设计。在分子设计与作用机制上，该产品透过特定化学修饰将活性分子转化为前药，使其在吸入沉积于肺部后，依赖肺组织内源性酶的缓慢裂解来持续释放活性成分。基于临床前研究，该设计预期可在将药物递送至深部肺组织的同时，平抑给药初期的血药浓度峰值(Cmax)并延长局部药物暴露时间，从而探索优化药物药代动力学(PK)特征的潜力。ICF001的首发适应症为动脉性肺动脉高压(PAH;WHO第1类)与间质性肺疾病相关肺动脉高压(PH-ILD;WHO第3类)。PAH是一种致死性罕见病;而PH-ILD则代表患者基数更庞大、现有疗法相对有限的领域。近年来，前沿科学研究与同类国际项目的临床探索进一步提示，ICF001所针对的特定作用通路具有抗肺动脉高压和抗纤维化的双重潜力。因此，基于这一独特机制，ICF001未来具备向间质性肺疾病相关肺纤维化，包括特发性肺纤维化(IPF)及进展性肺纤维化(PPF)等更大规模患者人群拓展的潜在空间。公告称，该申请的受理是集团在高壁垒呼吸管线的开发上进入临床开发的重要里程碑。公司认为，ICF001的研发战略重点在于探索其在耐受性和滴定效率方面的潜在改善，具体聚焦以下方向：其一，透过分子结构与制剂工艺的协同优化，致力于提高药物载荷效率，减轻给药负担，提升气道耐受性;其二，旨在优化体内暴露特征，在控制血药浓度峰值的同时改善总体暴露表现，以支持更可控的给药策略。如相关机制与临床获益在后续研究中得到进一步证实，预计将支持更具操作性及可控性的吸入给药策略，提升长期用药依从性，优化疗效发挥潜力，扩大药物的临床可及性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619882190","isCrawlerRequest":true}